The latest price target for Estrella Immunopharma (NASDAQ:ESLA) was reported by D. Boral Capital on February 21, 2025. The analyst firm set a price target for $16.00 expecting ESLA to rise to within 12 months (a possible 1584.21% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Estrella Immunopharma (NASDAQ:ESLA) was provided by D. Boral Capital, and Estrella Immunopharma maintained their buy rating.

There is no last upgrade for Estrella Immunopharma

There is no last downgrade for Estrella Immunopharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Estrella Immunopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Estrella Immunopharma was filed on February 21, 2025 so you should expect the next rating to be made available sometime around February 21, 2026.

While ratings are subjective and will change, the latest Estrella Immunopharma (ESLA) rating was a maintained with a price target of $16.00 to $16.00. The current price Estrella Immunopharma (ESLA) is trading at is $0.95, which is out of the analyst’s predicted range.